Creative Planning’s Cellectar Biosciences CLRB Stock Holding History

Creative Planning’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-100	Closed	-$36K	–	2135
2021 Q2	$36K	Hold	100	–	–	﹤0.01%	1962
2021 Q1	$48K	Buy	+100	New	+$59.5K	﹤0.01%	2357
2018 Q2	–	Sell	-5	Closed	-$18K	–	2073
2018 Q1	$18K	Buy	+5	New	+$17.9K	﹤0.01%	1895
2016 Q3	–	Sell	-1	Closed	-$14K	–	4582
2016 Q2	$14K	Buy	+1	New	+$8.37K	﹤0.01%	3014

Other funds holding CLRB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Creative Planning's CLRB Position: Q3 2021 in Review

Creative Planning sold out of Cellectar Biosciences (CLRB) in Q3 2021, closing a stake of 100 shares — an estimated $36K sold.

Creative Planning first reported a position in CLRB in Q2 2016 and held it in 4 quarters. The position peaked at $48K in Q1 2021. 38 funds tracked by Wall St. Rank hold CLRB as of Q3 2021.

Creative Planning reported no remaining Cellectar Biosciences position as of Q3 2021 after selling out during the quarter.
Creative Planning sold 100 Cellectar Biosciences shares in Q3 2021, an estimated $36K.
Creative Planning first reported a position in Cellectar Biosciences in Q2 2016 and held it in 4 quarters.
Creative Planning's Cellectar Biosciences position peaked at $48K in Q1 2021.
38 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2021.

Based on Creative Planning's 13F filing for Q3 2021, filed 10 Nov 2021.